Cancer Clinical Trial
Official title:
Identification of Novel Biomarkers to Aid in the Detection of Occult Cancer in Patients With Venous Thromboembolism
Venous thromboembolism is a common and serious complication in cancer, and is associated with
a substantially increased morbidity and mortality. Furthermore, VTE may be the earliest sign
of cancer. Recent studies, however, fail to show a clinical benefit of extended cancer
screening in this patient population. Better risk prediction models are therefore warranted
to identify VTE patients who would benefit from a rapid and extensive cancer screening.
Inflammation and hypercoagulability are considered hallmarks of cancer, and emerging light is
being shed on the potential of various markers of inflammation and coagulation in cancer
diagnostics and prognostics. Among the inflammatory and thrombotic processes linked to cancer
is the neutrophil release of web-like nuclear chromatin (DNA and histones), referred to as
neutrophil extracellular traps (NETs). Driven by the tumor environment, NETs have recently
been shown to play a central role in tumor progression, metastasis, and tumor-associated
thrombosis.
The investigators hypothesize that an enhanced inflammatory state may be predictive of an
underlying cancer in patients presenting with VTE. The present study is an ongoing
prospective study with the primary aim to investigate the diagnostic potential of markers of
inflammation, including markers of NETs, in detecting occult cancer in patients presenting
with VTE. Secondary aims are to include other biomarkers of cancer, and to assess whether any
or a combination of these biomarkers may be prognostic of occult cancer, recurrent thrombotic
events, mortality, or cancer disease progression in VTE patients with an underlying
malignancy.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
| Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
| Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
| Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
| Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
| Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
| Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
| Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
| Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
| Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
| Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
| Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
| Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
| Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
| Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
| Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
| Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
| Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
| Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|
||
| Recruiting |
NCT05318196 -
Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
|